Car-t cell therapy for relapsed poems syndrome
Part of Blood & lymphatic, Brain & nervous system, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new cell therapy called KQ-2003 CAR-T for people with POEMS syndrome that has relapsed or not responded to other treatments. The study aims to see if this personalized treatment can help control the disease and improve symptoms like nerve damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have POEMS syndrome that has returned or has not improved with standard treatments.
- You have not had CAR-T cell therapy targeting BCMA and CD19 before.
- You are not pregnant or breastfeeding, and you do not have active infections like hepatitis or HIV.
- Your heart, lungs, and major organs are functioning well enough, and you have adequate venous access for blood collection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
This trial tests a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people newly diagnosed with POEMS syndrome. It aims to see how well this treatment helps control the disease and its symptoms.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This early-stage trial uses a type of immune cell therapy (CAR-T cells) to treat severe autoimmune diseases that attack the nervous system, such as NMOSD, myasthenia gravis, CIDP, and multiple sclerosis. The goal is to see if this treatment can stop the immune system from damaging nerves when other treatments have failed.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to attack cancer cells that have certain markers (CD19 or BCMA). It is for people with blood cancers like multiple myeloma or certain lymphomas that have not responded to multiple prior treatments. The goal is to see if this treatment can help when other options have failed.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Hear when a new POEMS Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.